Tivozanib (Fotivda) is a kinase inhibitor indicated for the treatment of adult patients with recurrent or refractory advanced renal cell carcinoma (RCC) who have received two or more prior systemic therapies.

How to Purchase Tivozanib (Fotivda)

Overseas Purchase

Patients may choose to consult and purchase Tivozanib at hospital pharmacies or legitimate drugstores in countries or regions where the medication has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase Through Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for Using Tivozanib (Fotivda)

Prevention and Control of Cardiovascular System Risks

Hypertension and Hypertensive Crisis: Hypertension occurs in 45% of patients, of which 22% are severe events (grade 3 or higher). Blood pressure must be controlled before treatment, and regular monitoring should be conducted 2 weeks after administration and monthly thereafter.

Heart Failure: The incidence rate is 1.6%, of which 1% are events of grade 3 or higher.

Arterial Thrombotic Events: The incidence rate is 2%, including fatal ischemic stroke.

Management of Special Populations for Medication Use

Surgical Patients: Discontinue Tivozanib for at least 24 days before elective surgery. After major surgery, administration of the medication should be considered only when the wound has completely healed.

Contraindications and Drug Interactions

Avoid concurrent use with strong CYP3A inducers.

Patients of Childbearing Age: Effective contraceptive measures must be taken during treatment and within 1 month after the last dose.

Authentication of Tivozanib (Fotivda) (Genuine vs. Counterfeit)

Accurate Identification of Packaging Features

1.34 mg Capsules: Bright yellow opaque cap and body, with "TIVZ" (on the cap) and "SD" (on the body) printed in dark blue ink.

0.89 mg Capsules: Dark blue opaque cap and body, with "TIVZ" (on the cap) printed in yellow ink and "LD" printed on the bright yellow body.

Verification of Regulatory Information

Patients can check the drug approval number and pharmaceutical manufacturer information through the official website of the National Medical Products Administration (NMPA).